Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. reported a leadership change in its finance function. On January 2, 2026, former Chief Financial Officer Naveen Kumar Amar resigned for personal reasons. The board then appointed Milan Rao as both Global Chief Operating Officer and the new Chief Financial Officer on January 6, 2026, with his roles effective January 16, 2026.
Rao brings more than three decades of executive experience across technology, healthcare and global services, including senior roles at Markets & Markets, Smart Energy Water, Wipro and GE Healthcare. Under a one-year services agreement effective January 16, 2026, he will receive monthly base compensation of $41,667 and a stock grant of 120,000 shares of common stock under the company’s 2016 Incentive Stock Plan, vesting in equal monthly installments of 10,000 shares, subject to continued engagement and plan terms.
SS Innovations International, Inc. reported that it has completed development of five new 5-millimeter surgical instruments intended for clinical use. These instruments are designed for procedures across multiple specialties, including pediatric, cardiac, and head and neck surgery, as well as other operations involving smaller anatomical structures.
The update was disclosed in a current report and accompanied by a press release filed as an exhibit, highlighting expansion of the company’s instrument portfolio for delicate, small-structure surgery.
SS Innovations International, Inc. disclosed that its Chairman and CEO, Dr. Sudhir Srivastava, took part in an interview with Nasdaq’s Live From MarketSite on November 13, 2025, which was published on December 16, 2025. The video can be viewed on Nasdaq’s Live From MarketSite website and via the company’s investor overview page. The company emphasizes that this interview is being furnished, not filed, under Regulation FD and is not incorporated by reference into other SEC reports, and it includes standard cautionary language about forward-looking statements and related risks.
SS Innovations International, Inc. (SSII) reported an insider transaction by a director and officer serving as COO - Americas. On 10/08/2025, the insider reported a transaction in common stock coded "G," indicating a gift of 3,300 shares at a price of $0.00 per share. After this transaction, the insider beneficially owns 7,863,588 shares of SSII common stock in direct ownership. No derivative securities transactions were reported.
SS Innovations International (SSII) reported an insider transaction by Chairman and CEO Sudhir Srivastava. On 11/05/2025, he reported a code G gift of 30,000 shares of common stock at $0. Following the transaction, he beneficially owns 112,553,014 shares indirectly through Sushruta Pvt. Ltd.
Srivastava is listed as a Director and 10% Owner, and the shares are held of record by an entity he controls.
SS Innovations International, Inc. (SSII) furnished an updated November 2025 Company Presentation under Item 7.01 (Regulation FD Disclosure). The presentation is attached as Exhibit 99.1.
The materials are deemed “furnished,” not “filed,” which limits their applicability under Section 18 of the Exchange Act and they are not incorporated by reference into other filings. The notice includes customary forward‑looking statements language, highlighting that actual results may differ due to risks described in the company’s periodic reports.
SS Innovations International (SSII) reported a technology milestone. The company announced the successful completion of the first telesurgery performed using its SSi Mantra Tele Surgeon Console. The system is a compact, self-contained, chair-based version of the larger SSi Mantra command center, designed for portability, smaller spaces, and telesurgery from varied settings, including physician offices.
The announcement was made on November 6, 2025, and a detailed press release was furnished as Exhibit 99.1.
SS Innovations International (SSII) furnished a press release discussing results of operations for the three and nine month periods ended September 30, 2025. The company made the disclosure under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and attached the press release as Exhibit 99.1.
The information in Items 2.02 and 7.01, and Exhibit 99.1, is deemed “furnished” rather than “filed,” and is not subject to Section 18 liabilities or incorporated by reference into other filings.
SS Innovations International (SSII) filed its quarterly report and reported strong top-line growth with continued losses. Q3 revenue was $12.83M, up from $4.39M a year ago, driven by system sales. Gross profit rose to $6.16M from $2.32M. The company posted a Q3 net loss of $3.72M and a year‑to‑date net loss of $9.66M, an improvement from $17.23M in the prior‑year period.
As of September 30, 2025, total cash, cash equivalents and restricted cash were $12.04M; current cash and cash equivalents were $5.68M. Working capital showed a surplus of $27.24M. Operating cash outflow was $17.02M year‑to‑date, partly offset by $24.79M of net financing inflows, including issuance of $28.0M of one‑year 7% convertible notes and subsequent conversions totaling 21.86M shares. Inventory increased to $20.04M from $10.21M to support demand.
The company disclosed “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and reliance on related‑party funding even after its April 2025 Nasdaq uplisting. During Q3, it sold 28 surgical robotic systems (55 year‑to‑date). Revenue was concentrated in India, which represented 94% of Q3 sales.
SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.
A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”